GeneSystem Co

GeneSystem Co Short-term Debt

The Short-Term Debt of GeneSystem Co (363250.KQ) as of Oct 29, 2026 is 850.00 M KRW. In the previous year, Short-Term Debt was 850.00 M KRW — a change of 0.00% (lower).

Short-term Debt

850.00 MKRW

YoY

0.00%

Last updated:

Short-Term Debt of GeneSystem Co is 2024 850.00 M KRW. Short-Term Debt of GeneSystem Co was 2023 850.00 M KRW. It decreases by 0.00% lower compared to the previous year.

The GeneSystem Co Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2018
400.00 M KRW
Jan 1, 2019
400.00 M KRW
Jan 1, 2020
850.00 M KRW
Jan 1, 2021
850.00 M KRW
Jan 1, 2022
850.00 M KRW
Jan 1, 2023
850.00 M KRW
Jan 1, 2024
850.00 M KRW
The GeneSystem Co Short-term Debt history
YEARShort-term DebtYoY
850.00 MKRW0.00%
850.00 MKRW0.00%
850.00 MKRW0.00%
850.00 MKRW0.00%
850.00 MKRW+112.50%
400.00 MKRW0.00%
400.00 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneSystem Co Stock analysis

What does GeneSystem Co do? GeneSystem Co., Ltd generates revenue through the development, manufacturing, and sale of PCR-based molecular diagnostic products. The company offers molecular diagnosis systems, biochips, test kits, and reaction reagents, targeting healthcare providers and laboratories seeking advanced in vitro diagnostic solutions. Its core business focuses on molecular diagnosis technology, complementing immunodiagnosis technology to deliver comprehensive diagnostic tools. The firm serves medical institutions requiring precise and efficient diagnostic equipment for disease detection and monitoring. The company's product portfolio includes platform-based molecular diagnostic systems, biochips, and test kits designed for laboratory use. These products are sold directly to healthcare facilities and diagnostic laboratories, supporting applications in infectious disease testing and genetic analysis. By leveraging its expertise in molecular diagnosis, GeneSystem Co., Ltd provides essential tools for medical professionals to enhance diagnostic accuracy and patient care. GeneSystem Co., Ltd's revenue streams are derived from the sale of diagnostic systems, biochips, and consumables such as test kits and reaction reagents. The firm's target market comprises healthcare institutions and laboratories that require reliable in vitro diagnostic technology. The company's focus on molecular diagnosis technology positions it as a key supplier in the diagnostic equipment sector, meeting the growing demand for advanced diagnostic solutions in healthcare. GeneSystem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneSystem Co stock

Short-Term Debt of GeneSystem Co is 850.00 M KRW in 2024.

Short-Term Debt of GeneSystem Co changed from 850.00 M KRW to 850.00 M KRW, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt GeneSystem Co since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's GeneSystem Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GeneSystem Co

All Key Metrics — GeneSystem Co